Incyte Corporation has named Herve Hoppenot, former president of Novartis Oncology, as president and CEO. Mr. Hoppenot, who also will join the Incyte Board of Directors, succeeds Paul A. Friedman, M.D. Dr. Friedman is retiring and will continue to serve on the Board.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
61.35 USD | -0.65% |
|
-1.62% | -2.29% |
14/06 | Incyte Insider Sold Shares Worth $1,149,840, According to a Recent SEC Filing | MT |
13/06 | Incyte Reports Tender Offer Results | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.29% | 1.38TCr | |
+2.99% | 9.48TCr | |
-3.68% | 3.76TCr | |
-11.61% | 3.33TCr | |
+74.21% | 2.79TCr | |
-13.40% | 1.59TCr | |
-12.21% | 1.15TCr | |
+188.83% | 1.09TCr | |
-53.94% | 927.07Cr | |
+6.44% | 909.1Cr |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Incyte Corporation Announces Executive Changes